( 1 of 1 ) |
United States Patent | 8,357,783 |
Dimitrov , et al. | January 22, 2013 |
Disclosed herein are isolated human monoclonal antibodies that specifically bind human mesothelin with a binding affinity of about 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human mesothelin in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed.
Inventors: | Dimitrov; Dimiter S. (Frederick, MD), Feng; Yang (Frederick, MD), Pastan; Ira H. (Potomac, MD) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Applicant: |
| ||||||||
Assignee: |
The United States of America as represented by the Secretary of the Department of Health and Human Services
(Washington,
DC)
N/A ( |
||||||||
Family ID: | 40756654 | ||||||||
Appl. No.: | 12/934,060 | ||||||||
Filed: | March 25, 2009 | ||||||||
PCT Filed: | March 25, 2009 | ||||||||
PCT No.: | PCT/US2009/038228 | ||||||||
371(c)(1),(2),(4) Date: | September 22, 2010 | ||||||||
PCT Pub. No.: | WO2009/120769 | ||||||||
PCT Pub. Date: | October 01, 2009 |
Application Number | Filing Date | Patent Number | Issue Date | ||
---|---|---|---|---|---|
61040005 | Mar., 2008 | ||||
Current U.S. Class: | 530/388.25 ; 424/130.1; 424/133.1; 424/141.1; 424/156.1; 435/7.1; 530/387.1; 530/388.1 |
Current International Class: | C07K 16/00 (20060101); A61K 39/395 (20060101); G01N 33/53 (20060101) |
Current CPC Class: | C07K 16/30 (20130101); G01N 33/57484 (20130101); C07K 2317/21 (20130101); C07K 2317/565 (20130101); C07K 2317/567 (20130101); C07K 2317/732 (20130101); C07K 2319/55 (20130101) |
5789650 | August 1998 | Lonberg et al. |
5798230 | August 1998 | Bornkamm et al. |
6083502 | July 2000 | Pastan et al. |
6146894 | November 2000 | Nicolaides et al. |
6153430 | November 2000 | Pastan et al. |
6770445 | August 2004 | Scholler et al. |
6809184 | October 2004 | Pasta et al. |
7081518 | July 2006 | Pastan et al. |
7368110 | May 2008 | Pastan et al. |
2005/0054056 | March 2005 | Ebel et al. |
2005/0123900 | June 2005 | Dimitrov et al. |
2005/0214304 | September 2005 | Pastan et al. |
2006/0204506 | September 2006 | Ebel et al. |
2007/0292390 | December 2007 | Dimitrov et al. |
0 871 492 | Nov., 2003 | EP | |||
WO 00/73346 | Dec., 2000 | WO | |||
WO 2005/014652 | Feb., 2005 | WO | |||
WO 2006/099141 | Sep., 2006 | WO | |||
WO 2006/113643 | Oct., 2006 | WO | |||
WO 2006/124641 | Nov., 2006 | WO | |||
WO 2007/118214 | Oct., 2007 | WO | |||
Bera et al., "Bivalent Disulfide-stabilized Fragment Variable Immunotoxin Directed against Mesotheliomas and Ovarian Cancer," Molecular Cancer Therapeutics, American Association of Cancer Research 1(2):79-84, Dec. 1, 2001. cited by applicant . Bergan et al., "Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment," Cancer Letters 255:263-274, 2007. cited by applicant . Chang et al., "Control of human mesothelin-expressing tumors by DNA vaccines," Gene Therapy 14:1189-1198, 2007. cited by applicant . Chang et al., "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers," Proc. Natl. Acad. Sci. U.S.A. 93:136140, Jan. 1996. cited by applicant . Chowdhury et al., "Improving antibody affinity by mimicking somatic hypermutation in vitro," Nature Biotechnology 17(1):568-572, Jun. 1, 1999. cited by applicant . Chowdhury et al., "Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity," Proc. Natl. Acad. Sci. U.S.A. 95(2):669-674, Jan. 1, 1998. cited by applicant . Fan et al., "Targeted Therapy against Human Lung Cancer in Nude Mice by High-Affinity Recombinant Antimesothelin Single-Chain Fv Immunotoxin.sup.1," Molecular Cancer Therapeutics 1:595-600, Jun. 2002. cited by applicant . Hassan et al., "Mesothelin targeted cancer immunotherapy," European Journal of Cancer 44(1):46-53, Oct. 22, 2007. cited by applicant . Hassan et al., "Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin," Cancer Immunity 7:20, Dec. 19, 2007. cited by applicant . Hassan et al., "Mesothelin: A new Target for Immunotherapy," Clinical Cancer Research 10:3937-3942, Jun. 15, 2004. cited by applicant . Hassan et al., "Antitumor Activity of SS(dsFv)PE38 and SS1(dsFv)PE38, Recombinant Antimesothelin Immunotoxins against Human Gynecologic Cancers Grown in Organotypic Culture in Vitro," Clinical Cancer Research 8:3520-3526, Nov. 2002. cited by applicant . Ho et al., "Mesothelin Expression in Human Lung Cancer," Clin. Cancer Res. 13(5):1571-1575, Mar. 1, 2007. cited by applicant . Li et al., "Human antibodies for immunotherapy development generated via a human B cell hybridoma technology," Proc. Natl. Acad. Sci. U.S.A. 103(10):3557-3562, Mar. 7, 2006. cited by applicant . Onda et al., "New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA," Clinical Cancer Research 11(16):5840-5846, Aug. 15, 2005. cited by applicant . Presta et al., "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function," Advanced Drug Delivery Reviews 58(5-6):640-656, Aug. 7, 2006. cited by applicant . Sato et al., "Pretargeted Radioimmunotherapy of Mesothelin-Expressing Cancer Using a Tetravalent Single-Chain Fv-Streptavidin Fusion Protein," The Journal of Nuclear Medicine 46(7):1201-1209, Jul. 2005. cited by applicant . Weiner, "Fully Human Therapeutic Monoclonal Antibodies," Journal of Immunotherapy 29(1):1-9, Jan./Feb. 2006. cited by applicant . Zhang et al., "Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice," Clin. Cancer Res. 12(15):79-84, Aug. 1, 2006. cited by applicant . Zhang et al., "Selection of a Novel gp41-specific HIV-1 Neutralizing Human Antibody by Competitive Antigen Panning," J. Immunol Methods 317(1-2):21-30, Dec. 20, 2006. cited by applicant . Zhu et al., "Potent Neutralization of Hendra and Nipah Viruses by Human Monoclonal Antibodies," Journal of Virology 80(2):891-899, Jan. 2006. cited by applicant . International Search Report and Written Opinion for PCT/US2009/038228, dated Jun. 30, 2010, 15 pages. cited by applicant. |